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BACKGROUND: A most important characteristic feature for poor prognosis in colorectal cancer (CRC) is the presence of lymph node
metastasis. Determination of carcinoembryonic antigen (CEA) mRNA levels in lymph nodes has proven powerful for quantification of
disseminated tumour cells. Here, we investigate the utility of human tissue kallikrein-related peptidase 6 (KLK6) mRNA as a
progression biomarker to complement CEA mRNA, for improved selection of patients in need of adjuvant therapy and intensified
follow-up after surgery.
METHODS: Lymph nodes of pTNM stage I-IV CRC- (166 patients/503 lymph nodes) and control (23/108) patients were collected at
surgery and analysed by quantitative RT–PCR.
RESULTS: Lymph node KLK6 positivity was an indicator of poor outcome (hazard ratio 3.7). Risk of recurrence and cancer death
increased with KLK6 lymph node levels. Patients with KLK6 lymph node levels above the 90th percentile had a hazard ratio of 6.5 and
76 months shorter average survival time compared to patients with KLK6 negative nodes. The KLK6 positivity in lymph nodes with
few tumour cells, that is, low CEA mRNA levels, also indicated poor prognosis (hazard ratio 2.8).
CONCLUSION: In CRC patients, lymph node KLK6 positivity indicated presence of aggressive tumour cells associated with poor
prognosis and high risk of tumour recurrence.
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The most important prognostic characteristic of colorectal cancer
(CRC) patients resected for cure is presence or absence of lymph
node metastasis (Chang et al, 2007; Iddings and Bilchik, 2007;
Nicastri et al, 2007). Approximately 50% of patients with tumour
positive lymph nodes, that is, stage III CRC (anyTN1-2M0) and
about 25% of the patients apparently without lymph node
involvement, that is, stage I (T1-2N0M0) and II (T3-4N0M0)
patients will recur (Bilchik et al, 2007; Iddings and Bilchik, 2007;
Nicastri et al, 2007). Therefore, it is of utmost importance to detect
tumour cells in lymph nodes, and to determine their metastatic
potential. Thus, undertreatment of stage I and II patients as well as
overtreatment of stage III patients may be avoided, improving
tailored adjuvant treatment and follow-up.
A significant number of stage I and II patients, who will
experience tumour recurrence probably harbour occult tumour
cells in their lymph nodes. This is most likely due to the
inadequate sensitivity of routine histopathological staining proce-
dure and to the insufficient number of examined lymph nodes
(Nicastri et al, 2007). Biomarkers, like carcinoembryonic antigen
(CEA) and cytokeratin 20 (CK20), can identify stage I and II
patients with tumour cells in their lymph nodes that are
undetectable by histopathology (O ¨berg et al, 2004; Ohlsson et al,
2006, 2012). We found, that real-time quantitative reverse
transcriptase–PCR (qRT–PCR) analysis of mRNA for selected
biomarkers is a superior method for tumour cell detection when
used with a specific probe and an RNA copy standard (O ¨berg et al,
2004; Ohlsson et al, 2006, 2012). A problem with currently
available biomarkers for CRC, including CEA, is that these are
normal colonic tissue components and not tumour specific
(Ohlsson et al, 2006, 2012). Thus, detection of CEA mRNA in
regional lymph nodes indicates that tumour cells are of colonic
origin but does not signify anything about tumour cell aggres-
siveness. Identification of a complementary marker to CEA
reflecting also invasiveness would be of great interest.
Human tissue kallikrein-related peptidase 6 (KLK6) belongs to
the human kallikrein gene family of serine proteases (Borgono and
Diamandis, 2004). Many of these are dysregulated in human
malignancies and have a role in cell growth regulation, angiogen-
esis, invasion and metastasis (Borgono and Diamandis, 2004;
Talieri et al, 2009). Kallikrein-related peptidase 6 is expressed in
ovarian cancer and appears to be an unfavourable progression
biomarker in this malignancy (Anisowicz et al, 1996; Hoffman
et al, 2002; Diamandis et al, 2003). Kallikrein-related peptidase 6
mRNA expression has been demonstrated in primary colorectal
tumours (Yousef et al, 2004; Ogawa et al, 2005), and a smaller
clinical study suggests that elevated KLK6 mRNA levels in the
primary tumour might correlate to poor prognosis (Ogawa et al,
2005). In a recent study, it was suggested that, in the primary
tumour, KLK6 mRNA together with 12 other biomarker mRNAs
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sform a classifier for poor prognosis of CRC patients in stage II but
not in stage III (A ˚gesen et al, 2012). At the protein level, KLK6 was
detected in primary CRC tumours but there is a discrepancy
between the two studies; whether it is detectable also in normal
colon mucosa (Kim et al, 2011; Petraki et al, 2012).
In this study, we have focused on analysis of KLK6 mRNA
expression in the lymph nodes of patients with CRC aiming at
improved staging and prediction of outcome.
MATERIALS AND METHODS
Patients
Surgery for CRC was carried out in 166 patients (81 men, 85
women, median age 72 (range 42–90) years). In all, 13 of the
tumours were located in the rectum and 153 in colon. Seven of the
rectal cancer patients received 25Gy of preoperative radiotherapy.
A locally radical tumour resection was carried out in all patients.
The tumour differentiation grade was poor, moderate and high in
11, 145 and 10 tumours, respectively. Routine hematoxylin and
eosin (H&E) staining was performed on 2351 lymph nodes, giving
a median of 13 (range 1–51) nodes per patient. According to the
TNM classification, 30 patients were in stage I (T1-2N0M0), 74 in
stage II (T3-4N0M0), 46 in stage III (anyTN1-2M0) and 16 in stage
IV (anyTanyNM1). A total of 34 patients (4 in stage II, 19 in stage
III and 11 in stage IV) received adjuvant chemotherapy after
surgery. Follow-up was performed on 1 January 2011. No patient
was lost at follow-up. The median follow-up time was 75 (range
33–147) months. Controls included 18 men and 5 women (median
age 25 years (range 10–61)) undergoing surgery for ulcerative
colitis (UC; n¼18), Crohn’s colitis (n¼3), rectal prolapse (n¼1)
and colon lipoma (n¼1).
Informed consent was obtained from the patients and in one
case his parents. The Research Ethics Committee of the Medical
Faculty, Umea ˚ University, Sweden, approved the study.
Lymph nodes
Lymph nodes were retrieved from the resected specimens and
bisected with separate, sterile knives. One half of each node was
fixed in 10% buffered formalin for routine H&E staining. The other
half was snap frozen in liquid nitrogen and stored at  701C until
RNA extraction (Ohlsson et al, 2009). From CRC patients, 503
lymph nodes (91, 253, 107 and 52 nodes from stage I, II, III and IV
patients, respectively) were collected. A median of two (range
1–15) lymph nodes was obtained per patient. From control
patients, 108 lymph nodes (82, 9, 13 and 4 nodes from UC,
Crohn’s colitis, colon lipoma and rectal prolapse patients,
respectively) were collected.
Primary and distant CRC tumour and normal colon tissue
In all, 113 samples from 85 primary tumours were analysed (22
samples were from 16 stage I patients, 44 samples from 35 stage II
patients, 41 samples from 25 stage III patients and 8 samples
from 8 stage IV patients). Primary tumour stage distribution
(pT1–pT4) was 2, 14, 55 and 13. The tumour differentiation grade
was poor, moderate and high in 11, 71 and 3 tumours, respectively.
The tumour samples, approximately 0.5 0.5 0.5cm in size,
were collected immediately after resection, snap-frozen and stored
at  701C until RNA extraction. Six normal colon samples
retrieved from the proximal or distal resection margin and two
distant liver metastases samples were also collected and treated
accordingly.
Epithelial cells from colon tissue
Colonic epithelial cells (ECs) were isolated from the normal colon
mucosa at the resection margins as described (Fahlgren et al,
2003).
Cell lines and peripheral blood mononuclear cells (PBMCs)
Total RNA from the human cell lines LS174T, HT29, T84, HCT8
and Caco2 (all colon carcinomas), Jurkat and Molt-4 (T-cell
lymphomas), B6 and KR4 (EBV-transformed B-cell lines), U266
(plasmacytoma cell line), U937 (monocyte-like cell line), K562
(erythroblastoid cell line), HL60 (granulocyte cell line) and FSU
(fibroblast cell line) was analysed. Peripheral blood mononuclear
cells were isolated from healthy adults by Ficoll-Isopaque gradient
centrifugation, and RNA extracted directly and after polyclonal
activation as described (Ohlsson et al, 2012).
RNA preparation
Total RNA was extracted using the acid guanidine phenol
chloroform method as described (Ohlsson et al, 2012). The RNA
concentration was measured in a NanoDrop ND-1000 Spectro-
photometer (NanoDrop Technologies, Wilmington, DE, USA), and
the integrity of the RNA was analysed in a 2100 Bioanalyzer using
an RNA nano-assay (Agilent Technologies, Santa Clara, CA, USA).
Microarray gene-expression analysis
From each sample analysed, 400ng of total RNA was converted to
biotinylated doublestranded cRNA according to the Illumina
Totalprep RNA Amplification Kit (Ambion, Austin, TX, USA).
The labelled cRNA samples were then hybridised on Sentrix
HumanRef-8_V2 Expression Beadchips (Illumina, San Diego, CA,
USA) incubated with streptavidin-Cy3 and scanned using the
Illumina Beadstation GX (Illumina).
Results were analysed by using Illumina Beadstudio software
(version 3.3) for direct hybridisation assays. Intensity data were
normalised by Beadstudios cubic spline algorithm with subtracted
background. Significant difference in expression was calculated
using the Beadstudio software Error Model Illumina Custom with
multiple testing corrections, using Benjamini and Hochberg false
discovery rate (Reiner et al, 2003). Difference in gene expression
was calculated as fold change, dividing the signal in individual
CRC samples of interest over the average signal of controls.
Real-time qRT–PCR
Kallikrein-related peptidase 6 mRNA occurs in different splice
forms (Pampalakis et al, 2004). Before deciding which transcript(s)
of KLK6 mRNA should be investigated in depth, we used three
commercially available TaqMan Gene Expression Assays
(Hs01100840_ml, Hs01105353_gl and Hs00160519_ml; Applied
Biosystems, Foster City, CA, USA) to determine the expression
levels of transcript A, transcript B and all transcripts, respectively,
in the test panel RNA samples described in Figure 1A. We found
that the assay detecting all known transcripts and the assay
detecting transcript B gave the same result with high mRNA
expression in primary CRC and CRC cell lines and no expression
in normal colon, immune cells or fibroblasts. The assay detecting
transcript A showed the same tissue specificity; however, the
expression levels were clearly lower (data not shown).
Consequently, a real time qRT–PCR assay with RNA copy
standard detecting all known splice-forms of KLK6 mRNA was
constructed by using the Taqman EZ technology (Applied
Biosystems) as described (Fahlgren et al, 2003; Ohlsson et al,
2012). Primer and probe sequences were: forward primer 50-CT
TATCCATCCACTGTGGGTC-30, reverse primer 50-TGGATCAC
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sAGCCCGGA-30 and probe 50-CACTGCAAAAAACCGAATCTTC
AGGTC-30. The reporter dye was FAM and the quencher dye
TAMRA. The RT–PCR profile was: 491C for 2min, 591C for
30min, 941C for 5min followed by 45 cycles of 931C for 20s and
611C for 1min. Emission from the released reporter dye was
measured by the ABI Prism 7700 Sequence Detection System
(Applied Biosystems). Serial dilutions of the RNA copy standard at
concentrations from 10
3 to 10
8 copies per ml were included in each
analysis. Concentrations in unknown samples were determined
from the standard curve and expressed as copies of mRNA per ml.
All qRT–PCR analyses were carried out in triplicates. The
reproducibility of the KLK6 assay was determined as described
(Ohlsson et al, 2012). The coefficient of variation (CV) based on
PCR ct-values was 1.0%. The mean CV for estimation of mRNA
content covering 10
3–10
8 RNA copies per reaction was 26.7%.
The concentration of 18S rRNA was determined in each sample
by real-time qRT–PCR for normalisation of mRNA levels as
described (Bas et al, 2004; Ohlsson et al, 2012). Results are
expressed as mRNA copies per unit of 18S rRNA.
Statistical analysis
Correlation between biomarker mRNA levels was analysed using
the non-parametric Spearman correlation coefficient. Differences
in biomarker mRNA levels between two patient groups were
analysed by two-tailed Mann–Whitney U test. Descriptive values of
mRNA levels are given as median and range or interquartile range
(IQR) from the 25th to 75th percentile.
Differences in disease-free survival and risk for recurrent
disease after surgery between patient groups were calculated
according to Kaplan–Meier survival model in combination with
the log-rank test and univariate Cox regression analysis. Patients
who died from causes other than CRC were considered as disease
free. Descriptive values of risk and survival time are given as mean
and 95% confidence interval (CI).
Correlations between mRNA levels, differences in mRNA levels,
differences in survival time and hazard ratios with a P-value o0.05
were considered to be statistically significant. The software utilised
was SPSS version 18 (IBM Corporation, Armonk, NY, USA).
RESULTS
To identify potential progression markers for CRC, we performed
microarray analysis of gene-expression using seven different CRC
RNA samples (H&E(þ) lymph nodes of four stage III patients and
the primary tumour from three of these) and seven control RNA
samples (lymph nodes from two UC patients, one Crohns’ colitis
patient, one colon lipoma patient and three normal colon EC
samples). Colorectal cancer samples were analysed individually
relative to all control samples as one group. The microarray data
were filtered by setting the inclusion criteria to a fold change of
X5, a statistical significance of Po0.05, and an intensity of X15.
Kallikrein-related peptidase 6 and 17 other genes fulfilled these
criteria in all seven CRC samples (Supplementary Table 1).
The microarray data was verified by analysing a panel of RNA
samples including primary CRC tumours, normal colon, CRC cell
lines, PBMCs, immune cell lines and a fibroblast cell line for KLK6
mRNA levels using a qRT–PCR assay that is specific and detects all
known splice-forms of KLK6 mRNA. Kallikrein-related peptidase 6
mRNA was expressed at relatively high levels in primary CRC
tumours with a median value of 3.0 mRNA copies/18S rRNA unit
(IQR: 0.9–8.6). Interestingly, KLK6 was not expressed in normal
colon or in any type of immune cell or in fibroblasts (o0.00001
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Figure 1 (A) Median KLK6 mRNA level in 85 primary CRC tumours (median: 3.0 mRNA copies/18S rRNA unit; range: 0.01–137), 6 normal colon tissue
samples (o0.00001 mRNA copies/18S rRNA unit), 6 normal colon EC samples (o0.00001 mRNA copies/18S rRNA unit) and mean of 3 determinations of
the indicated cell lines and resting and activated human PBMC. KLK6 mRNA levels in LS174T, HT29, T84, HCT8 and Caco2 cells were 82, 275, 337, 23 and
0.4 mRNA copies/18S rRNA unit, respectively. KLK6 mRNA levels in PBMCs and all other cell lines: o0.00001 mRNA copies/18S rRNA unit. (B) KLK6
mRNA levels at four different sites within individual primary tumours. Ten tumours were analysed, two from stage I patients (P1–P2), three from stage II
patients (P3–P5) and five from stage III patients (P6–P10).
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smRNA copies/18S rRNA unit; Figure 1A). Of note, KLK6 mRNA
was not expressed in activated PBMCs, in sharp contrast to the
biomarker matrix metalloproteinase 7/matrilysin that was
expressed at high levels in lymph nodes and activated PBMCs as
compared with the resting PBMCs (Ohlsson et al, 2006). Analysis
of samples obtained from different sites within the same tumour
revealed that expression of KLK6 showed large intra-tumour
heterogeneity. Kallikrein-related peptidase 6 levels could vary
more than 100-fold between different sites in the same tumour
(Figure 1B), while this was not the case for CEA levels in the same
samples (Ohlsson et al, 2012). There was no correlation between
KLK6 mRNA levels and pT-stages (data not shown).
Kallikrein-related peptidase 6 mRNA was highly expressed in
2/2 liver metastases (2.3 and 1.7 mRNA copies/18S rRNA unit), but
was not detected in normal liver.
Lymph node KLK6 mRNA level increases with TNM stage
In the following, each patient is represented by the node with the
highest biomarker level. Figure 2A shows the KLK6 mRNA levels
in the lymph nodes of 166 CRC patients and 23 controls with
benign disease. Kallikrein-related peptidase 6 mRNA was not
detected in lymph nodes of controls (o0.00001 mRNA copies/18S
rRNA unit) but in 20% of lymph nodes of stage I patients (6/30),
11% of stage II patients (8/74), 54% of stage III patients (25/46)
and 75% of stage IV patients (12/16). Kallikrein-related peptidase
6(þ) lymph nodes had X0.0095 mRNA copies/18S rRNA unit.
The KLK6 levels in nodes of the few stage I and II patients who had
a KLK6(þ) lymph node were low (median 0.062 copies/18S rRNA
unit) and clearly lower than most KLK6(þ) nodes of stage III and
IV patients (median 2.06 copies/18S rRNA unit; Po0.0001).
Risk of recurrence increases with increasing lymph node
KLK6 mRNA levels
A total of 51 patients had died from CRC or were living with
recurrent disease at follow-up (median 75 months, range 33–147),
whereas 115 patients were apparently cured or had died of causes
unrelated to CRC. Using Cox regression analysis, the risk of
recurrence (hazard risk ratio) for the KLK6(þ) and KLK6( )
populations was calculated. There was a 3.7-fold (95% CI: 2.1–6.4)
greater risk of recurrence of disease for KLK6(þ) compared with
KLK6( ) patients (Table 1).
To evaluate whether the actual KLK6 mRNA level in lymph
nodes is of importance for the risk of recurrence, we divided the
patients into 10 groups of equal numbers according to the KLK6
mRNA levels. Up to the 70th percentile, patients had no detectable
KLK6 mRNA. Using the cutoff values at the 70th, 80th and 90th
percentiles hazard risk ratios were calculated (Table 1). Compared
with KLK6( ) patients, KLK6(low) were not significantly
different. Kallikrein-related peptidase 6(int) patients showed a
3.7-fold (95% CI: 1.7–8.0) increased risk compared with KLK6( )
patients and KLK6(high) an 6.5-fold (95% CI: 3.2–13.3) increased
risk, both found to be statistically highly significant (Table 1).
Survival time after surgery decreases with increasing
lymph node KLK6 mRNA levels
The cumulative survival of lymph node KLK6(þ) and lymph node
KLK6( ) patients estimated by Kaplan–Meier analyses is shown
in Figure 3A and Table 1. The mean survival time for KLK6( )
patients was 117 months and 54 months for KLK6(þ) patients,
giving a highly significant difference in survival of 63 months.
Kallikrein-related peptidase 6(low), KLK6(int) and KLK6(high)
patients showed 49, 63 and 76 months shorter mean survival times
than KLK6( ) patients, respectively (Figure 3B and Table 1).
Thus, short survival time correlates with high KLK6 mRNA levels
in resected lymph nodes.
This result was underscored when prognosis was analysed by
plotting the proportion of patients who had died from CRC or were
living with recurrent disease against years after surgery
(Figure 3C). Colorectal cancer patients with high lymph node
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Figure 2 KLK6 mRNA levels in lymph nodes of stage I to IV CRC
patients and control patients (Ctr). Each of the 166 CRC patients and 23
control patients is represented by the lymph node with the highest KLK6
level. (A) All patients, (B) patients with at least one H&E(þ) lymph node
available for mRNA analysis (C) patients with only H&E( ) lymph nodes
available for mRNA analysis. Filled circles represent patients who have died
in CRC or are living with recurrent disease. Open circles represent living,
disease-free patients and patients who have died from other causes than
CRC. For clarity dots indicating KLK6( ) patients who have died from
CRC are positioned slightly above those who are alive in (B) and (C).
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sKLK6 mRNA levels died earlier than patients with intermediate
and in particular with low KLK6 mRNA levels. The differences
were most pronounced within the first 2 years. At this time, there
was no difference in the proportion of patients who had died from
recurrent disease in the respective marker negative patient group.
Kallikrein-related peptidase 6 mRNA identifies stage I and
II patients with lymph node occult disease
Stage I and II patients are by definition H&E( ), thus presumed
to have no tumour cells in their lymph nodes. In all, 14 of 104 stage
I and II patients were KLK6(þ). Interestingly, two of the
KLK6(þ) patients had died from recurrent CRC at follow-up
(Figure 2C). In addition, 2 of the H&E( ) KLK6(þ) patients had
died from unrelated diseases, whereas 10 were alive without
apparent recurrence. Thus, KLK6 mRNA analysis detects positive
cells in 13% of the patients who were negative in H&E staining and
some of these succumbed from CRC.
Altogether, 14 stage I and II patients had died from CRC or were
living with tumour recurrence (Figure 2C). All but two were
H&E( ) KLK6( ) and therefore missed by both types of lymph
node analysis. Possibly, they were missed because tumour cells
spread by the hematogenous route or because too few lymph nodes
were analysed.
Table 1 Comparative analysis of average survival time after surgery and risk for recurrence of disease of CRC patients with KLK6(þ) or KLK6( ) lymph
nodes
KLK6 mRNA levels
(copies/18S rRNA unit)
Survival time after
surgery (months)
Risk for recurrence
of CRC
Patient group Category Level
Percentile of
patient population Average
Difference
vs marker( ) P-value
Hazard ratio
(95% CI) P-value
All CRC patients (n¼166) KLK6( ) o0.0001 0–69 117
a
KLK6(þ) 40.0001 70–100 54 63 o0.0001 3.66 (2.10–6.38)
b o0.0001
KLK6( ) o0.0001 0–69 117
KLK6(low) 0.0095–0.083 70–79 67 49 o0.0001 1.99 (0.85–4.65) NS
KLK6(int) 0.083–3.63 80–89 53 63 o0.0001 3.70 (1.70–8.04) 0.001
KLK6(high) 43.63 90–100 40 76 o0.0001 6.52 (3.20–13.28) o0.0001
H&E( ) NA 111
H&E(þ)N A 4 4 6 7o0.0001 5.11 (2.91–8.97) o0.0001
CRC patients with intermediate
CEA mRNA levels
c (n¼73)
KLK6( ) o0.0001 NA 121
KLK6(þ) 40.0001 NA 68 53 0.04 2.78 (1.01–7.69) 0.05
H&E( ) NA 116
H&E(þ) NA 66 50 NS 2.36 (0.53–10.54) NS
Abbreviations: CI¼confidence interval; NA¼not applicable; NS¼not significant (P-value 40.05).
aMean survival time after surgery as calculated by cumulative survival analysis
according to Kaplan–Meier.
bRisk ratio with 95% confidence interval (CI) as calculated according to univariate Cox regression analysis.
cLymph node CEA mRNA levels between
0.013 and 3.67 mRNA copies/18S rRNA unit, that is, above the level in lymph nodes of controls and below the clinical cutoff for CEA mRNA (Ohlsson et al, 2012).
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Figure 3 Cumulative survival curves according to Kaplan-Meier for CRC patients with (A) KLK6(þ) lymph nodes, (B) KLK6(high), KLK6(int), and
KLK6(low) lymph nodes, and (A, B) KLK6( ) lymph nodes. The difference in average survival time between the KLK6(þ), KLK6(high), KLK6(int) and
KLK6(low) versus KLK6( ) patients is given as a delta value in months for each patient group. (C) Proportion of CRC patients with recurrent disease in
marker positive (marker (þ)) and marker negative (marker( )) groups as a function of time after surgery. (K) Patients with a KLK6 mRNA level above the
70th percentile, that is, 0.0095 mRNA copies/18S rRNA unit; (’) Patients with a KLK6 mRNA level above the 80th percentile, that is, 0.00083 mRNA
copies/18S rRNA unit; (m) Patients with a KLK6 mRNA level above the 90th percentile, that is, 3.63 mRNA copies/18S rRNA unit; ( and dotted line)
Patients with a CEA mRNA level above the clinical cutoff at the 80th percentile, that is, 3.67 mRNA copies/18S rRNA unit. n¼numbers of patients in the
respective group.
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detect tumour cells in H&E( ) lymph nodes
A total of 503 lymph nodes were analysed for KLK6 mRNA, CEA
mRNA and H&E. Almost all H&E(þ) nodes were KLK6(þ) and
CEA(þ), that is, 88% with detected KLK6 mRNA and 94% with a
CEA mRNA level above control nodes. Notably, 11% (53/471) and
35% (164/471) of the H&E( ) nodes were KLK6(þ) and
CEA(þ), respectively. Most interestingly, among the H&E( )
nodes, all KLK6(þ) nodes had a significant CEA value (correla-
tion coefficient r¼0.75, Po0.0001). No lymph node was KLK6(þ)
CEA( ). Twenty-four percent of the H&E( ) nodes were
KLK6( ) CEA( ). Thus, routine H&E staining misses a number
of nodes with tumour cells, of which a third also expresses KLK6.
Kallikrein-related peptidase 6 mRNA analysis identifies
patients as node positive even in H&E( ) lymph nodes
A difficulty in comparing the prognostic value of KLK6 mRNA
analysis and H&E staining is that a much larger number of lymph
nodes have been analysed by H&E staining than by KLK6 mRNA.
Therefore, the patients were divided into two groups: the first
group comprised patients from whom we had the opportunity to
analyse KLK6 mRNA levels in H&E(þ) nodes and the second
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Figure 4 Correlation between KLK6 and CEA mRNA levels in the highest lymph node of stage I (A), stage II (B), stage III (C) and stage IV (D) CRC
patients. Dotted lines represent the clinical cutoff for CEA, that is, 3.67 mRNA copies/18S rRNA unit, and solid lines represent the highest CEA mRNA level
in lymph nodes of controls, that is, 0.013 mRNA copies/18S rRNA unit. Filled circles represent patients who have died in CRC or are living with recurrent
disease. Open circles represent living, disease-free patients and patients who have died from other causes than CRC. (E) Cumulative survival curves
according to Kaplan–Meier for KLK6(þ) and KLK6( ) CRC patients with CEA mRNA levels between the highest control level and the clinical cutoff level
(CEA(int)). The difference in average survival time between the KLK6(þ) and KLK6( ) patients is given as a delta value in months. n¼numbers of patients
in the respective group.
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available for mRNA analysis (Figure 2B and C). In the first group,
KLK6 mRNA identified 16 of the 19 patients who had died from
CRC or were living with recurrent disease (Figure 2B). In the
second group, 18 stage III and IV patients had died from CRC. Of
these, nine patients were KLK6(þ) (Figure 2C). Thus, 50% of
H&E( ) nodes from stage III and IV patients that succumbed
from CRC were identified by KLK6 mRNA. On the other hand, 4 of
the 27 (14%) H&E(þ) nodes from stage III and IV patients were
KLK6( ) and 3 of them had died from CRC (Figure 2B).
Complementary KLK6 mRNA analysis identifies aggressive
tumour cells in lymph nodes with few occult tumour cells
Previous comparative studies demonstrated that CEA mRNA per-
forms better for the detection of disseminated tumour cells in the
lymph nodes of patients with CRC than 10 other investigated
biomarker mRNAs (Ohlsson et al, 2006, 2012). Analysing CEA
mRNA, there is a group of patients with intermediate levels
(CEA(int)), that is, higher than controls but below the clinical cutoff
established by Cox regression analysis (Ohlsson et al, 2012). We
explored whether KLK6 would be useful as a complementary
biomarker in detecting aggressive tumour cells in CEA(int) patients.
Figures 4A–D show the results of KLK6  and CEA mRNA
analyses of lymph nodes from CRC patients of all tumour stages. In
the CEA(int) group of patients, one stage II (Figure 4B), five stage
III (Figure 4C) and two stage IV (Figure 4D) patients had died
from CRC had KLK6(þ) nodes. Thus, KLK6(þ) identifies a
subgroup of patients, who on the basis of CEA only, would not
have been classified as patients at risk for tumour recurrence. On
the other hand, there were eight additional CEA(int) KLK6( )
patients who had died from CRC who would have been undetected
by both biomarkers.
Carcinoembryonic antigen(int) patients were divided into
KLK6(þ) and KLK6( ) groups and analysed for the risk of
recurrence and cumulative survival. Kallikrein-related peptidase
6(þ) was an indicator for poor prognosis with a hazard ratio of
2.8 and on average 53 months shorter survival (Table 1 and
Figure 4E). Thus, KLK6 positivity even in lymph nodes with few
tumour cells is a sign of tumour aggressiveness.
DISCUSSION
The aim of this study was to identify a tumour progression marker
for CRC that could be used alone or complementary to CEA mRNA
analysis identifying high-risk patients with poor prognosis and in
need of adjuvant chemotherapy, but also identifying patients with
good prognosis that should be spared from additional therapy.
In this study, we identified KLK6 mRNA as a most promising
progression biomarker for CRC. Kallikrein-related peptidase 6
mRNA was expressed in all analysed primary tumours, but was not
expressed in normal colon. This finding is of great interest as all
other CRC biomarkers studied so far have shown high expression
levels in normal adult colon (Ohlsson et al, 2006, 2012). Thus,
KLK6 mRNA expression in colon appears to be a sign of malignant
transformation. Our findings are in line with previous studies on
KLK6 mRNA and protein in primary CRC tumour and normal
colon, although low levels of KLK6 mRNA and protein was
reported in a few samples of normal colon tissue (Ogawa et al,
2005; Kim et al, 2011). One recent study reports KLK6 protein in
normal colon but at the same time these authors report poor
prognosis for CRC patients with intense KLK6 staining of primary
tumours (Petraki et al, 2012). We believe that the minor
discrepancy at the mRNA level and the discrepancies at the
protein level relate to the specificities of the mRNA assays and
antibody reagents, respectively.
To determine whether KLK6 is a useful prognostic marker for
survival, we focused on studies of the mesenteric lymph nodes
because the mere presence of tumour cells, particularly in several
lymph nodes, is in itself a sign of poor prognosis. That lymph node
analysis is to be preferred rather than analysis of primary tumour
is supported by a recent study, which suggests that KLK6 mRNA
analysis of primary tumour is useful only in stage II patients
(A ˚gesen et al, 2012). Kallikrein-related peptidase 6 mRNA analysis
was also compared with CEA mRNA analysis and H&E staining of
the same lymph nodes. The following tentative conclusions could
be drawn: (1) KLK6(þ) lymph nodes were always CEA(þ). Thus,
KLK6 mRNA only occurred in lymph nodes with cells derived
from the epithelium of colon or rectum. (2) Kallikrein-related
peptidase 6 mRNA was expressed in only 10–20% of lymph nodes
from stage I and II patients but in 53% and 75% of lymph nodes
from stage III and IV patients, respectively. Moreover, the mRNA
levels in the KLK6(þ) stage I and II patients were 30 times lower
than in stage III and IV patients. (3) The hazard ratio for the risk
of recurrence was 3.7 times higher in the KLK6(þ) group, as
compared to the KLK6( ) group, and the difference in the mean
survival time was 63 months between groups. (4) The actual KLK6
mRNA level in the lymph node was directly related to the risk of
recurrence. Thus, patients with the highest KLK6 levels had
the highest hazard risk ratio and the shortest survival time.
(5) Patients with high KLK6 mRNA levels in lymph nodes
tended to succumb from recurrence within 3 years after surgery.
(6) A group of stage III and IV patients with intermediate CEA
mRNA levels expressed high KLK6 mRNA. These patients had
CEA values below the clinical cutoff and would therefore, on the
basis of CEA alone, not have been considered to be at risk for
recurrent disease and possibly undertreated (Ohlsson et al, 2012).
Kallikrein-related peptidase 6 mRNA identified more than 60%
of the patients in this group who died from recurrent CRC. (7)
Kallikrein-related peptidase 6 mRNA was highly expressed in liver
metastases. We conclude that KLK6 mRNA is a most valuable
progression marker in CRC.
The functional properties of KLK6 support the notion that it is a
progression marker. As a secreted serine protease KLK6 has the
potential of being instrumental in the metastatic process (Borgono
and Diamandis, 2004). Thus, KLK6(þ) tumour cells may have a
greater chance of escaping the primary site and to metastasise to
distant sites than KLK6( ) tumour cells. Kallikrein-related
peptidase 6 can degrade basic constituents of the extracellular
matrix and the basement membrane such as fibrinogen, collagen I
and IV, fibronectin, vitronectin and laminin (Magklara et al, 2003).
Activating K-RAS mutations are common in CRC, occurring in
about 30% of all CRC cases. Activation of K-RAS involves
increased proliferation, evasion of apoptosis and increased
migration and invasion. One important explanation for KLK6
mRNA being expressed in CRC is that KLK6 functions as a
mediator of K-RAS-dependent migration (Henkhaus et al, 2008).
Moreover, KLK6 reduces E-cadherin levels in the cell membrane,
probably by indirectly affecting ectodomain shedding leading to
reduced cell–cell adhesion (Klucky et al, 2007).
Combined analysis of CEA and KLK6 mRNAs in lymph nodes
show great potential in identifying patients at high risk of tumour
recurrence. We believe that the combined analysis of CEA and
KLK6 mRNA in lymph nodes will become a powerful prognostic
tool in CRC. This can easily be achieved by utilising qRT–PCR
amendable to automation.
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